Reducing Cardiometabolic Risk: What Cardiovascular Outcomes Trials Tell Us About Incretin-Based Therapies

Please visit answersincme.com/KAF860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Jill Trinacty, MD, FRCPC, ABOM. In this activity, an expert in endocrinology discusses incretin-based therapies for the management of cardiometabolic risk. Upon completion of this activity, participants should be better able to: Describe the role of incretin-based therapies in cardiovascular risk reduction; Compare cardiovascular outcomes evidence across incretin-based therapies to inform clinical discussions; and Recognize opportunities to identify and address cardiometabolic risk in a multidisciplinary team setting.